Cipla's Advair Generic Debut In Sight, More Platform Deals On Radar Post Ethris
Stem Cell Therapy Well Received
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.
